What is Iovance Biotherapeutics, Inc.'s market cap?

Iovance Biotherapeutics, Inc. (IOVA) has a market capitalization of $2.2B and trades on NASDAQ.

What is Iovance Biotherapeutics, Inc.'s revenue and profitability?

Iovance Biotherapeutics, Inc. generated $285.6M in trailing twelve-month revenue with a net loss of $353.9M, representing a net margin of -123.9%. Gross margin stands at 36.7%, with free cash flow of -$305.0M. These figures are based on the Q1 2026 filing.

Who are Iovance Biotherapeutics, Inc.'s competitors?

Iovance Biotherapeutics, Inc.'s key competitors include Bristol-Myers Squibb, Gilead Sciences, Citius Oncology, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Iovance Biotherapeutics, Inc. partner with?

Iovance Biotherapeutics, Inc.'s notable partners include National Cancer Institute, European Medicines Agency.

Where is Iovance Biotherapeutics, Inc. headquartered?

Iovance Biotherapeutics, Inc. is headquartered in United States of America and employs approximately 557 people. It has been publicly traded since 2010.

Iovance Biotherapeutics, Inc.

IOVA

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company specializing in the development and delivery of tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.

Market cap

$2.19B+145%

Revenue$285.6M+34.3%

Net income-$353.9M+5.7%

Free cash flow-$305.0M+12.2%

EPS (diluted)-$1.13+24.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$71.4MMiss by $6.4M EPS-$0.19In line

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$87.7M

EPS estimate-$0.17

Financials

Q1 2026

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation & ratios

Valuation

See full

Market cap$2.19B+145%

Enterprise value$2.04B+125%

P/S7.7×+3.6×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Segments

By product

See full

Amtagvi$60.2M+38.2%

Proleukin$11.2M+94.8%

By segment

See full

Single Reportable$71.4M+44.8%

Competitors

By market cap

Gilead Sciences$162.05B+15.3%

Bristol-Myers Squibb$127.75B+32.1%

ImmunityBio, Inc.$7.3B+213%

Iovance Biotherapeutics, Inc.$2.2B+122%

CTO

Citius Oncology, Inc.$51.7M-64.7%

Instil Bio$48.5M-75.1%

Intensity Therapeutics, Inc.$12.4M+40.2%

GT Biopharma$12.0M+75.3%

By revenue growth

ImmunityBio, Inc.+352%

Iovance Biotherapeutics, Inc.+34.3%

Gilead Sciences+3.5%

Bristol-Myers Squibb+1.8%

By net margin

Gilead Sciences30.99%+10.2pp

Bristol-Myers Squibb15.01%+3.8pp

Iovance Biotherapeutics, Inc.-123.9%+52.6pp

ImmunityBio, Inc.-606.15%+704pp

Profile

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company specializing in the development and delivery of tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers. The company utilizes a proprietary manufacturing process to create individualized, polyclonal T cell therapies that harness a patient's own immune system to recognize and destroy cancer cells. Their platform transforms complex research-based cell therapies into scalable, commercially accessible treatments for advanced cancer patients.

Competitive position

Pioneer in the first FDA-approved one-time T cell therapy for solid tumor cancers, transitioning from a research-focused entity to a commercial-stage leader in TIL technology.

GeographiesUnited States, Canada, United Kingdom, Australia, Switzerland, European Union

Customer segmentsAdvanced Melanoma Patients, Specialized Oncology Centers, Healthcare Payors

Business modelIndividualized Cell Therapy Manufacturing, Biopharmaceutical Research and Development

SuppliersPatient Tissue Collection, Specialized Cell Culture Media, Manufacturing Equipment Providers, Logistics and Cold Chain Services

CustomersAuthorized Treatment Centers, Specialty Pharmacies, Government and Private Health Insurers

CountryUnited States of America

Listed2010

Employees557.0

CEOFrederick G. Vogt

SectorHealthcare

IndustryBiotechnology

Websiteiovance.com

FilingsSEC EDGAR

Ask your AI about Iovance Biotherapeutics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s market cap?: Iovance Biotherapeutics, Inc. (IOVA) has a market capitalization of $2.2B and trades on NASDAQ.
What is Iovance Biotherapeutics, Inc.'s revenue and profitability?: Iovance Biotherapeutics, Inc. generated $285.6M in trailing twelve-month revenue with a net loss of $353.9M, representing a net margin of -123.9%. Gross margin stands at 36.7%, with free cash flow of -$305.0M. These figures are based on the Q1 2026 filing.
Who are Iovance Biotherapeutics, Inc.'s competitors?: Iovance Biotherapeutics, Inc.'s key competitors include Bristol-Myers Squibb, Gilead Sciences, Citius Oncology, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Iovance Biotherapeutics, Inc. partner with?: Iovance Biotherapeutics, Inc.'s notable partners include National Cancer Institute, European Medicines Agency.
Where is Iovance Biotherapeutics, Inc. headquartered?: Iovance Biotherapeutics, Inc. is headquartered in United States of America and employs approximately 557 people. It has been publicly traded since 2010.